Equitable Access to GLP-1 Receptor Agonists-Essential but Not Accessible.

Efforts to improve access to GLP-1 receptor agonists are crucial as they are now on the WHO’s Essential Medicines list, yet remain largely inaccessible in low- and middle-income countries.

• Why it matters: Addressing this gap is vital because equitable access to these medicines can significantly impact the management of diabetes and related conditions globally, reducing health disparities.
• What they did: The perspective highlights necessary actions to enhance accessibility, focusing on policy changes, affordability, and distribution strategies in resource-limited settings.
• The result: Implementing these measures could lead to broader availability of GLP-1 receptor agonists, enabling better health outcomes and advancing health equity worldwide.